NRG-BR002 did not show improved progression-free or overall survival from adding metastasis-directed ablation in its selected breast-cancer population. This result is distinct from local palliation.
Randomised phase 2/3 design in breast cancer with no more than four metastases, a controlled primary and no progression during up to twelve months of first-line systemic treatment. All visible metastases had to be amenable to SBRT or surgery. The 2026 report enrolled 129 patients and analysed 125 eligible participants; 79 percent had HR-positive, HER2-negative disease. Ablation was SBRT in 93 percent.
With median follow-up 29.9 months and 72 progression events, the study did not meet the progression endpoint needed to proceed to phase 3. Its outcome does not establish that ablation is incapable of local control or symptom relief, or answer every breast subtype, later therapy or metastatic setting.
Demonstrates why a local-treatment name and a small number of metastases do not establish added patient-level benefit. Preserve the studied population, systemic strategy and endpoint.
Shares Systemic versus local therapy, SBRT / SABR (stereotactic radiotherapy), Breast cancer (all types) and the tags education-audit, local-treatment.
Shares Systemic versus local therapy, Breast cancer (all types) and the tags education-audit, local-treatment.
Shares Systemic versus local therapy and the tags education-audit, local-treatment.
Shares SBRT / SABR (stereotactic radiotherapy), Breast cancer (all types) and the tags education-audit, local-treatment.
Shares Breast cancer (all types) and the tags education-audit, local-treatment.
Shares Breast cancer (all types) and the tags education-audit, local-treatment.
Shares Breast cancer (all types) and the tags education-audit, local-treatment.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/